DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+31.38%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.02B
AUM Growth
+$2.02B
(+40%)
Cap. Flow
+$255M
Cap. Flow
% of AUM
12.6%
Top 10 Holdings %
Top 10 Hldgs %
42.84%
Holding
68
New
16
Increased
12
Reduced
21
Closed
5
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$90.5M |
| 2 |
Ascendis Pharma
ASND
|
$82.6M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$67.6M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$48.1M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$44.9M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$226M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$64.8M |
| 3 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$61.5M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$24.4M |
| 5 |
Keros Therapeutics
KROS
|
$18.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $126M | 5.75% | 7,000,000 +2,500,000 | +56% | +$44.9M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $115M | 5.26% | 861,000 +361,000 | +72% | +$48.1M |
|
3
Travere Therapeutics
TVTX
$1.56B
| $98.6M | 4.51% | 4,000,000 +419,300 | +12% | +$10.3M |
|
4
NovoCure
NVCR
$1.38B
| $98.3M | 4.5% | 1,293,761 -47,539 | -4% | -$3.61M |
|
|
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $90.5M | 4.15% | +1,462,800 | New | +$90.5M |
|
|
6
Ascendis Pharma
ASND
$11.8B
| $82.6M | 3.78% | +800,000 | New | +$82.6M |
|
|
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
| $67.6M | 3.1% | +2,369,210 | New | +$67.6M |
|
|
BCYC
8
Bicycle Therapeutics
BCYC
$511M
| $67.5M | 3.09% | 2,900,000 | – | – |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $62.6M | 2.87% | 738,863 +84,498 | +13% | +$7.16M |
|
|
KDNY
10
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $59M | 2.7% | 3,000,000 -430,110 | -13% | -$8.46M |
|
11
Immunovant
IMVT
$2.56B
| $55M | 2.52% | 9,860,246 +405,246 | +4% | +$2.26M |
|
|
AGEN
12
Agenus
AGEN
$133M
| $54M | 2.47% | 26,325,000 +4,083,583 | +18% | +$8.37M |
|
13
Beam Therapeutics
BEAM
$1.66B
| $47.6M | 2.18% | 1,000,000 -250,000 | -20% | -$11.9M |
|
14
Kura Oncology
KURA
$686M
| $43.5M | 1.99% | 3,186,083 -511,886 | -14% | -$6.99M |
|
15
Aurinia Pharmaceuticals
AUPH
$1.58B
| $42.7M | 1.96% | +5,677,372 | New | +$42.7M |
|
16
Dyne Therapeutics
DYN
$1.92B
| $40.4M | 1.85% | 3,184,200 -315,800 | -9% | -$4.01M |
|
17
Viridian Therapeutics
VRDN
$1.5B
| $40.4M | 1.85% | 1,970,290 +800,000 | +68% | +$16.4M |
|
18
Repare Therapeutics
RPTX
$71.7M
| $37.9M | 1.74% | 3,127,667 +420,005 | +16% | +$5.09M |
|
19
Acumen Pharmaceuticals
ABOS
$82.4M
| $37.9M | 1.74% | 3,778,818 +678,818 | +22% | +$6.81M |
|
20
Esperion Therapeutics
ESPR
$448M
| $37.8M | 1.73% | 5,636,587 -363,413 | -6% | -$2.43M |
|
21
Nkarta
NKTX
$151M
| $37M | 1.7% | 2,814,844 | – | – |
|
22
Heron Therapeutics
HRTX
$207M
| $36.1M | 1.65% | +8,548,387 | New | +$36.1M |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $33.2M | 1.52% | +3,374,394 | New | +$33.2M |
|
24
Fate Therapeutics
FATE
$120M
| $29.4M | 1.35% | 1,311,113 -706,892 | -35% | -$15.8M |
|
25
Pliant Therapeutics
PLRX
$101M
| $29.2M | 1.34% | +1,399,744 | New | +$29.2M |
|